| Equity |
7 Equity (a) Share capital | | | | | 30 June
2026 | | | 30 June
2025 | | | 30 June
2024 | | | 30 June
2026 | | | 30 June
2025 | | | 30 June
2024 | | | | Notes | | Shares | | | Shares | | | Shares | | | $ | | | $ | | | $ | | Ordinary shares | | | | | | | | | | | | | | | | | | | Ordinary Shares Fully paid | | | | | 3,544,216,160 | | | | 2,364,949,502 | | | | 460,367,051 | | | | 209,933,371 | | | | 176,558,493 | | | 100,681,716 | | | | 7(a)(i) | | | 3,544,216,160, | | | | 2,364,949,502 | | | | 460,367,051 | | | | 209,933,371 | | | | 176,558,493 | | | 100,681,716 | (i) Movements in ordinary shares: | Details | | Notes | | Number of
shares | | | Total
$ | | | Balance at 1 July 2023 | | | | | 339,313,037 | | | | 97,230,329 | | | Issue at $0.070 pursuant to rights issue (2023-12-08) | | | | | 30,197,244 | | | | 2,113,808 | | | Issue at $0.105 of forfeiture shares as per employment contract (2023-12-14) | | | | | 2,128,815 | | | | 223,526 | | | Issue of ordinary shares at $0.0864 in lieu of cash for services rendered (2024-01-05) | | | | | 1,200,013 | | | | 103,681 | | | Issue at $0.07 pursuant to rights issue shortfall (2024-01-31) | | | | | 18,714,145 | | | | 1,309,990 | | | Issue at $0.07 pursuant to rights issue shortfall (2024-02-09) | | | | | 1,950,000 | | | | 136,500 | | | Issue at $0.059 pursuant to Lind agreement (2024-02-14) | | | | | 20,000,000 | | | | - | | | Issue at $0.059 as part of Pharma15 acquisition (2024-03-04) | | | | | 25,856,470 | | | | 1,297,022 | | | Issue at $0.052 pursuant to Lind agreement (2024-03-12) | | | | | 5,769,231 | | | | 300,000 | | | Issue at $0.045 pursuant to Lind agreement (2024-04-15) | | | | | 6,666,667 | | | | 300,000 | | | Issue at $0.035 pursuant to Lind agreement (2024-05-16) | | | | | 8,571,429 | | | | 300,000 | | | Less: Transaction costs arising on share issues | | | | | - | | | | (2,633,140 | ) | | Balance at 30 June 2024 | | | | | 460,367,051 | | | | 100,681,716 | | | | | | | | | | | | | | | Balance at 1 July 2024 | | | | | 460,367,051 | | | | 100,681,716 | | | Issue of ordinary shares at $0.040 pursuant to issue of securities(2024-07-01) | | | | | 597,130,727 | | | | 23,885,229 | | | Issue of ordinary shares at $0.040 pursuant to Tranche 2 placement shares (2024-08-21) | | | | | 858,056,603 | | | | 34,322,264 | | | Issue of ordinary shares at $0.040 pursuant to Tranche 2 placement shares (2024-08-21) | | | | | 14,031,195 | | | | 561,248 | | | Issue of ordinary shares at $0.050 pursuant to Lantheus investment (2024-08-23) | | | | | 149,625,180 | | | | 7,481,259 | | | Issue of ordinary shares at $0.040 pursuant to issue of placement shares (2024-09-13) | | | | | 93,750,000 | | | | 3,750,000 | | | Issue of ordinary shares at $0.036 pursuant to the achievement of a milestone (2024-12-13) | | | | | 20,594,438 | | | | 741,400 | | | Issue of ordinary shares at $0.036 pursuant to forfeiture shares (2024-12-16) | | | | | 7,091,615 | | | | 219,840 | | | Issue of ordinary shares at $0.060 pursuant to issue of placement shares to Lantheus (2025-01-20) | | | | | 133,333,333 | | | | 8,000,000 | | | Issue of ordinary shares at $0.025 pursuant to a milestone payment (2025-06-12) | | | | | 30,969,360 | | | | 774,234 | | | Less: Transaction costs arising on share issues | | | | | - | | | | (3,858,697 | ) | | Balance at 30 June 2025 | | | | | 2,364,949,502 | | | | 176,558,493 | | | Balance at 1 July 2025 | | | | | 2,364,949,502 | | | | 176,558,493 | | | Issue at $0.030 pursuant to rights issue (2025-10-24) | | | | | 415,706,190 | | | | 12,471,186 | | | Issue at $0.030 pursuant to rights issue (2025-12-05) | | | | | 12,599,991 | | | | 378,000 | | | Issue at $0.030 pursuant to rights issue (2025-12-09) | | | | | 750,960,477 | | | | 22,528,814 | | | | | | | | | | | | | | | Less: Transaction costs arising on share issues | | | | | - | | | | (2,003,122 | ) | | Balance at 30 June 2026 | | | | | 3,544,216,160 | | | | 209,933,371 | | (b) Other reserves The following table shows a breakdown of the statement of financial position line item ‘other reserves and the movements in these reserves during the year and period, respectively. A description of the nature and purpose of each reserve is provided below the table. | | | | | Shares to
be issued | | | Share-based
payments | | | Equity
settled
payments | | | Foreign
currency
translation | | | Total
other
reserves | | | | | Notes | | $ | | | $ | | | $ | | | $ | | | $ | | | At 1 July 2023 | | | | | - | | | | 10,778,749 | | | | 330,001 | | | | (747,293 | ) | | | 10,361,457 | | | Currency translation differences | | | | | - | | | | - | | | | - | | | | 202,956 | | | | 202,956 | | | Other comprehensive loss | | | | | - | | | | - | | | | - | | | | 202,956 | | | | 202,956 | | | Transactions with owners in their capacity as owners | | | | | | | | | | | | | | | | | | | | | | | | Issue of options as part of forfeiture payments | | | | | - | | | | 44,796 | | | | (44,796 | ) | | | - | | | | - | | | Issue of shares as part of forfeiture payments | | | | | - | | | | - | | | | (147,038 | ) | | | - | | | | (147,038 | ) | | Issue of options | | 7(b)(ii) | | | - | | | | 3,327,468 | | | | - | | | | - | | | | 3,327,468 | | | Shares to be issued | | | | | 24,185,229 | | | | - | | | | - | | | | - | | | | 24,185,229 | | | At 30 June 2024 | | | | | 24,185,229 | | | | 14,151,013 | | | | 138,167 | | | | (544,337 | ) | | | 37,930,072 | | | | | | | | | | | | | | | | | | | | | | | | | | | At 1 July 2024 | | | | | 24,185,229 | | | | 14,151,013 | | | | 138,167 | | | | (544,337 | ) | | | 37,930,072 | | | Currency translation differences | | | | | - | | | | - | | | | - | | | | 464,034 | | | | 464,034 | | | Other comprehensive loss | | | | | 24,185,229 | | | | 14,151,013 | | | | 138,167 | | | | (80,303 | ) | | | 38,394,106 | | | Transactions with owners in their capacity as owners | | | | | | | | | | | | | | | | | | | | | | | | Transfer from Share-based payments to equity settled payments | | | | | | | | | (136,454 | ) | | | 136,454 | | | | | | | | - | | | Issue of options as part of forfeiture payments | | | | | - | | | | 43,506 | | | | (43,506 | ) | | | - | | | | - | | | Issue of shares as part of placement | | | | | (23,885,229 | ) | | | - | | | | - | | | | | | | | (23,885,229 | ) | | Issue of shares as part of forfeiture payments | | | | | - | | | | - | | | | (200,394 | ) | | | - | | | | (200,394 | ) | | Lapse of forfeiture payment | | | | | - | | | | - | | | | (30,721 | ) | | | - | | | | (30,721 | ) | | Issue of options | | | | | - | | | | 2,157,778 | | | | - | | | | - | | | | 2,157,778 | | | Cancellation of shares to be issued relating to Lind | | | | | (300,000 | ) | | | - | | | | - | | | | - | | | | (300,000 | ) | | Expiration of options | | | | | - | | | | (2,797,451 | ) | | | - | | | | - | | | | (2,797,451 | ) | | Forfeiture of options | | | | | - | | | | (221,170 | ) | | | - | | | | - | | | | (221,170 | ) | | At 30 June 2025 | | | | | - | | | | 13,197,222 | | | | - | | | | (80,303 | ) | | | 13,116,919 | | | | | | | Shares to
be issued | | | Share-based
payments | | | Equity
settled
payments | | | Foreign
currency
translation | | | Total
other
reserves | | | | | Notes | | $ | | | $ | | | $ | | | $ | | | $ | | | At 1 July 2025 | | | | | - | | | | 13,197,222 | | | | - | | | | (80,303 | ) | | | 13,116,919 | | | Currency translation differences | | | | | - | | | | - | | | | - | | | | 621,440 | | | | 621,440 | | | Other comprehensive loss | | | | | - | | | | 13,197,222 | | | | - | | | | 541,137 | | | | 13,738,359 | | | Transactions with owners in their capacity as owners | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Issue of options | | 7(b)(ii) | | | - | | | | 2,740,119 | | | | - | | | | - | | | | 2,740,119 | | | Expiration of options | | | | | - | | | | (1,730,159 | ) | | | - | | | | - | | | | (1,730,159 | ) | | Forfeiture of options | | | | | - | | | | (334,164 | ) | | | - | | | | - | | | | (334,164 | ) | | At 30 June 2026 | | | | | - | | | | 13,873,018 | | | | - | | | | 541,137 | | | | 14,414,155 | | (i) Nature and purpose of other reserves Shares to be issued Share coded as shares to be issued were issued on 1 July 2024 as part of the capital raise announced in June 2024. Share-based payments The share-based payment reserve records items recognized as expenses on valuation of share options issued to key management personnel, other employees and eligible contractors. Foreign currency translations Exchange differences arising on translation of foreign controlled entities are recognized in other comprehensive income or loss as described in note 20(c) and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. Equity settled payments Equity settled payments reserve records items recognized as expenses on valuation of shares to be issued to key management personnel and other employees for forfeiture of long term incentives at previous employers. (ii) Movements in options: | Details | | Number of
options | | | Total
$ | | | Balance at 30 June 2023 | | | 151,710,315 | | | | 10,642,295 | | | Issue of unlisted options | | | 16,455,224 | | | | 763,778 | | | Issue of ESOP unlisted options | | | 18,795,456 | | | | 742,379 | | | Expense for share-based payments for options previously issued | | | - | | | | 1,866,107 | | | | | | | | | | | | | Balance at 30 June 2024 | | | 186,960,995 | | | | 14,014,559 | | | Issue of unlisted options | | | 968,815,574 | | | | 29,985 | | | Issue of ESOP unlisted options | | | 164,472,155 | | | | 1,396,110 | | | Forfeiture of options | | | (4,351,176 | ) | | | (221,170 | ) | | Expiration of options | | | (163,605,052 | ) | | | (2,797,451 | ) | | Expense for share-based payments for options previously issued | | | - | | | | 775,189 | | | Balance at 30 June 2025 | | | 1,152,292,496 | | | | 13,197,222 | | | Issue of unlisted options | | | 214,480,666 | | | | 1,939,747 | | | Issue of listed options | | | 1,179,266,658 | | | | - | | | Expiration of options | | | (6,605,604 | ) | | | (1,730,159 | ) | | Forfeiture of options | | | (37,224,710 | ) | | | (334,164 | ) | | Expense for share-based payments for options previously issued | | | - | | | | 800,372 | | | Balance at 30 June 2026 | | | 2,502,209,506 | | | | 13,873,018 | | (c) Other equity | | | 30 June | | | 30 June | | | 30 June | | | | | 2026
$ | | | 2025
$ | | | 2024
$ | | | Contingent issue of equity | | | - | | | | 849,544 | | | | 849,544 | | | | | | - | | | | 849,544 | | | | 849,544 | | Contingent issue of equity includes amounts related to the value of consideration shares to be issued to the Pharma15 shareholders once certain milestones are met as per their agreement. Due to the impairment of the Pharma15 asset, the contingent consideration was reversed out at 30 June 2026. For more information, please refer to note 13(g).
|